| US 7,608,270 B2 | ||
| Dosage form | ||
| Stephen Thomas Beckett, York (United Kingdom); Stephen Lawrence Atkin, Hessle (United Kingdom); and Grahame Mackenzie, Hull (United Kingdom) | ||
| Assigned to University of Hull, Hull (United Kingdom) | ||
| Filed on Jun. 25, 2004, as Appl. No. 10/877,042. | ||
| Claims priority of provisional application 60/482922, filed on Jun. 27, 2003. | ||
| Prior Publication US 2005/0002963 A1, Jan. 06, 2005 | ||
| Int. Cl. A61K 36/00 (2006.01) | ||
| U.S. Cl. 424—195.15 [424/195.17; 424/725; 424/780; 424/275.1] | 82 Claims |
| 1. A pharmaceutical or dietetic dosage form comprising an effective quantity of an active substance chemically or physically
bound to, or encapsulated within, a support selected from: an exine coating of spores of a plant, moss, fungus, bacterium
or algae or a fragment thereof, wherein:
the active substance comprises one or more drugs, one or more dietetic substances, or a mixture thereof;
the coating comprises sporopollenin derived from plant, moss, fungus, bacterium or algae spores;
the dosage form is in the form of a foodstuff or a pharmaceutical selected from the group consisting of a tablet, a capsule,
a soft gel capsule, an ovule, an elixir, granules, an inhaleable formulation comprising an inhaleable carrier, a suppository,
a pessary, a gel, a hydrogel lotion, a cream, an ointment, a dusting powder and a skin patch; and
any spore protein present in the dosage form is present at less than 0.5% of the exine coating.
|